In this podcast, an advanced practice provider and a medical oncologist discuss their choices of a few key trials in CLL/SLL presented at the ASCO Annual Meeting 2022 and how the findings may impact patient care. Topics include new evidence on the safety and efficacy of combination therapy with a BTK inhibitor and BCL-2 inhibitor along with analyses of the impact of racial and socioeconomic disparities on disease survival. Download the supplemental PowerPoint slides below for additional education and to share with your team.

Acknowledgment

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


If you have already listened to the podcast, use the button below to access the post-test and evaluation and receive your certificate.

Faculty

John M. Burke, MD Associate Chair US Oncology Hematology Research Program Rocky Mountain Cancer Centers Aurora, Colorado

Amy Esposito, FNP-C Nurse Practitioner Rocky Mountain Cancer CenterAurora, Colorado

Development Widget